留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

系统性红斑狼疮与人乳头瘤病毒感染及相关疫苗

徐东 张奉春

徐东, 张奉春. 系统性红斑狼疮与人乳头瘤病毒感染及相关疫苗[J]. 协和医学杂志, 2020, 11(3): 252-257. doi: 10.3969/j.issn.1674-9081.20200042
引用本文: 徐东, 张奉春. 系统性红斑狼疮与人乳头瘤病毒感染及相关疫苗[J]. 协和医学杂志, 2020, 11(3): 252-257. doi: 10.3969/j.issn.1674-9081.20200042
Dong XU, Feng-chun ZHANG. Systemic Lupus Erythematosus, Human Papilloma Virus Infection and Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 252-257. doi: 10.3969/j.issn.1674-9081.20200042
Citation: Dong XU, Feng-chun ZHANG. Systemic Lupus Erythematosus, Human Papilloma Virus Infection and Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 252-257. doi: 10.3969/j.issn.1674-9081.20200042

系统性红斑狼疮与人乳头瘤病毒感染及相关疫苗

doi: 10.3969/j.issn.1674-9081.20200042
基金项目: 

中国医学科学院医学与健康科技创新工程 2019-I2M-2-008

详细信息
    通讯作者:

    张奉春  电话:010-69158792, E-mail:zhangfccra@aliyun.com

  • 中图分类号: R593.24;R511

Systemic Lupus Erythematosus, Human Papilloma Virus Infection and Vaccine

More Information
  • 摘要: 人乳头瘤病毒(human papilloma virus, HPV)能引起宫颈良性病变(如尖锐湿疣)、癌前病变以及宫颈癌, 尤其是血清型16和18, 与宫颈癌的发生密切相关。系统性红斑狼疮(systemic lupus erythematosus, SLE)患者HPV感染较普通人群概率更高且多种HPV亚型感染常见, 同时异常巴氏涂片、高度宫颈上皮内病变的风险亦显著增加, 因此在SLE患者中预防HPV感染非常必要。疫苗是预防感染性疾病最有效的工具之一。已有3种HPV疫苗获批上市, 分别为2价(针对HPV 16、18型)、4价(针对HPV 6、11、16、18型)和9价(针对HPV 6、11、16、18、31、33、45、52、58型), 用以阻止宫颈癌前病变和宫颈癌, 4价和9价疫苗同时也可阻止HPV引起的良性疾病, 比如尖锐湿疣。目前多项前瞻性研究显示, HPV疫苗在SLE患者中安全有效, 可产生保护性应答。2019年欧洲抗风湿病联盟发表了成人自身炎症性风湿性疾病(autoimmune inflammatory rheumatic diseases, AⅡRD)患者疫苗应用的更新建议, 推荐AⅡRD患者, 特别是SLE患者, 应按照一般人群的建议接种HPV疫苗。此外, 特别值得注意的是, HPV疫苗接种并不能替代常规宫颈不典型增生筛查, 亦不能治疗HPV感染, SLE患者即使接种了HPV疫苗, 也应定期进行筛查。
    利益冲突  无
  • [1] Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus:association with human papillomavirus infection[J]. Arthritis Rheum, 2004, 50:3619-3625. doi:  10.1002/art.20616
    [2] Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AⅡRD):a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AⅡRD[J]. RMD Open, 2019, 5:e001041. doi:  10.1136/rmdopen-2019-001041
    [3] Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection?[J].Lupus, 2010, 19:1485-1491. doi:  10.1177/0961203310372952
    [4] Amaral JL, Araújo MV, Dias GA, et al. Clinical and epidemiological study of human papillomavirus infection in women with systemiclupus erythematosus in eastern brazilian amazon[J].Acta Reumatol Port, 2017, 42:47-54. http://europepmc.org/abstract/MED/27750272
    [5] Lyrio LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus[J]. Rheumatol Int, 2013, 33:335-340. doi:  10.1007/s00296-012-2426-0
    [6] García-Carrasco M, Mendoza-Pinto C, Rojas-Villarraga A, et al. Prevalence of cervical HPV infection in women with systemic lupus erythematosus:A systematic review and meta-analysis[J]. Autoimmun Rev, 2019, 18:184-191. doi:  10.1016/j.autrev.2018.09.001
    [7] Raposo A, Tani C, Costa J, et al. Human papillomavirus infection and cervical lesions in rheumatic diseases:a systematic review[J]. Acta Reumatol Port, 2016, 41:184-190. https://www.ncbi.nlm.nih.gov/pubmed/27682966
    [8] Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus:A metaanalysis of the literature[J]. Autoimmun Rev, 2014, 13:730-735. doi:  10.1016/j.autrev.2014.03.001
    [9] Grein IH, Groot N, Lacerda MI, et al. HPV infection and vaccination in Systemic Lupus Erythematosus patients:what we really should know[J]. Pediatr Rheumatol Online J, 2016, 14:12. doi:  10.1186/s12969-016-0072-x
    [10] Bateman H, Yazici Y, Leff L, et al. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE:a preliminary study[J]. Lupus, 2000, 9:542-544. doi:  10.1177/096120330000900711
    [11] Yu SL, Chan PK, Wong CK, et al. Antagonist-mediated down-regulation of toll-like receptors increases the preval-ence of human papillomavirus infection in systemic lupus erythematosus[J]. Arthritis Res Ther, 2012, 14:R80. doi:  10.1186/ar3803
    [12] Feldman CH, Liu J, Feldman S, et al. Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus Receiving Immunosuppressive Drugs[J]. Lupus, 2017, 26:682-689. doi:  10.1177/0961203316672928
    [13] Santana IU, Gomes Ado N, Lyrio LD, et al.Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions:a systematic review[J]. Clin Rheumatol, 2011, 30:665-672. doi:  10.1007/s10067-010-1606-0
    [14] Shi LH, Huang JY, Liu YZ, et al.Risk of systemic lupus erythematosus in patients with human papillomavirus infection:a population-based retrospective cohort study[J]. Lupus, 2018, 27:2279-2283. doi:  10.1177/0961203318809179
    [15] Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine[J]. J Exp Ther Oncol, 2009, 8:65-76. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=0556df4ad8e86aaab985bd8e3d696a7f
    [16] Natale C, Giannini T, Lucchese A, et al. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences[J]. Immunol Cell Biol, 2000, 78:580-585. doi:  10.1046/j.1440-1711.2000.00949.x
    [17] Segal Y, Dahan S, Calabro M, et al. HPV and systemic lupus erythematosus:a mosaic of potential crossreactions[J]. Immunol Res, 2017, 65:564-571. doi:  10.1007/s12026-016-8890-y
    [18] World Health Organization.Electronic address:sageexec-sec@who.int.Human papillomavirus vaccines:WHO position paper, May 2017-recommendations[J].Vaccine, 2017, 35:5753-5755.
    [19] Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults:Updated Recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019, 68:698-702. doi:  10.15585/mmwr.mm6832a3
    [20] 中华预防医学会妇女保健分会.子宫颈癌综合防控指南[M].北京:人民卫生出版社, 2017:37-40.
    [21] Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes:a systematic review and meta analysis[J]. Lancet Infect Dis, 2015, 15:565-580. doi:  10.1016/S1473-3099(14)71073-4
    [22] Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human pappillomavirus vaccine efficacy against the most stringent cervicalneoplasia end-point-registry-based follow-up of three cohorts from randomized trials[J]. BMJ Open, 2017, 7:e015867. doi:  10.1136/bmjopen-2017-015867
    [23] Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus:a case-control study[J]. Ann Rheum Dis, 2013, 72:659-664. doi:  10.1136/annrheumdis-2012-201393
    [24] Mok CC, Ho LY, To CH.Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus[J]. Vaccine, 2018, 36:3301-3307. doi:  10.1016/j.vaccine.2018.04.056
    [25] Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years[J]. Pediatr Rheumatol Online J, 2013, 11:29. doi:  10.1186/1546-0096-11-29
    [26] Heijstek MW, Scherpenisse M, Groot N, et al. Immuno-genicity of the bivalent human papillomavirus vaccine in adolescents withjuvenile systemic lupus erythematosus or juvenile dermatomyositis[J]. J Rheumatol, 2013, 40:1626-1627. doi:  10.3899/jrheum.130246
    [27] Dhar JP, Essenmacher L, Dhar R, et al.The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus[J]. Hum Vaccin Immunother, 2018, 14:2318-2322. doi:  10.1080/21645515.2018.1469592
    [28] Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden:cohort study[J]. BMJ, 2013, 347:f5906. doi:  10.1136/bmj.f5906
    [29] Israeli E, Agmon-Levin N, Blank M, et al. Adjuvants and autoimmunity[J]. Lupus, 2009, 18:1217-1225. doi:  10.1177/0961203309345724
    [30] Bragazzi NL, Bridgewood C, Sharif K, et al. HPV vaccines and lupus:current approaches towards preventing adverse immune cross-reactivity[J]. Expert Rev Vaccines, 2019, 18:31-42. doi:  10.1080/14760584.2019.1557519
    [31] Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events:a case-control assessment of the vaccine adverse event reporting system (VAERS) database[J]. Immunol Res, 2017, 65:46-54. doi:  10.1007/s12026-016-8815-9
    [32] Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection?[J].Lupus, 2012, 21:158-161. doi:  10.1177/0961203311429556
    [33] Miranda S, Chaignot C, Collin C, et al. Human papillomavirus vaccination and risk of autoimmune diseases:A large cohort study of over 2million young girls in France[J]. Vaccine, 2017, 35:4761-4768. doi:  10.1016/j.vaccine.2017.06.030
    [34] Chao C, Klein NP, Velicer CM, et al.Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine[J]. J Intern Med, 2012, 271:193-203. doi:  10.1111/j.1365-2796.2011.02467.x
    [35] Dhar JP, Essenmacher L, Dhar R, et al. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus[J]. Vaccine, 2017, 35:2642-2646. doi:  10.1016/j.vaccine.2017.04.001
    [36] Genovese C, LA Fauci V, Squeri A, et al. HPV vaccine and autoimmune diseases:systematic review and meta-analysis of the literature[J]. J Prev Med Hyg, 2018, 59:E194-E199. http://www.researchgate.net/publication/328779437_HPV_vaccine_and_autoimmune_diseases_systematic_review_and_meta-analysis_of_the_literature
    [37] Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome[J]. Ann Rheum Dis, 2017, 76:476-485. doi:  10.1136/annrheumdis-2016-209770
    [38] Furer V, Rondaan C, Heijstek MW, et al.2019 update of EULAR recommendation for vaccination in adult patients with autoimmune inflammatory rheumatic diseases[J]. Ann Rheum Dis, 2020, 79:39-52. doi:  10.1136/annrheumdis-2019-215882
  • 加载中
计量
  • 文章访问数:  293
  • HTML全文浏览量:  29
  • PDF下载量:  86
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-02-21
  • 刊出日期:  2020-05-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!